Robert S. Ohgami

Robert S. Ohgami, MD, PhD

Languages spoken: English

Clinical Locations

Craig H. Neilsen Rehabilitation Hospital

801-646-8000

Pathology

801-585-0100

Pathology

801-581-2507

  • Dr. Robert Ohgami was an undergraduate at Princeton University and an MD/PhD MSTP student in Harvard-MIT’s Health Sciences and Technology Program (HST). He went on to complete residency and fellowship at Stanford University in anatomic pathology and hematopathology.

    He has been a research and clinical faculty member at Stanford University and UCSF and served in leadership positions as a Director of the Molecular Pathology Core, Associate Program Director in Anatomic Pathology, and a Division Chief of Hematopathology. He is an Associate Editor for Frontiers in Oncology, on the editorial board of several journals including the Journal of Molecular Diagnostics, and a contributing author for the 2022 hematopathology WHO blue book. After several years of running an independently funded translational research lab, he was honored with a Berard-Dorfman Founders award in 2016 for his work in Hematopathology.

    Dr. Ohgami is a Professor of Pathology at the University of Utah and Chief Medical Director for Research and Development in Integrated Oncology and Genomics at ARUP.

  • Dr. Robert Ohgami was an undergraduate at Princeton University and an MD/PhD MSTP student in Harvard-MIT’s Health Sciences and Technology Program (HST). He went on to complete residency and fellowship at Stanford University in anatomic pathology and hematopathology.

    He has been a research and clinical faculty member at Stanford University and UCSF and served in leadership positions as a Director of the Molecular Pathology Core, Associate Program Director in Anatomic Pathology, and a Division Chief of Hematopathology. He is an Associate Editor for Frontiers in Oncology, on the editorial board of several journals including the Journal of Molecular Diagnostics, and a contributing author for the 2022 hematopathology WHO blue book. After several years of running an independently funded translational research lab, he was honored with a Berard-Dorfman Founders award in 2016 for his work in Hematopathology.

    Dr. Ohgami is a Professor of Pathology at the University of Utah and Chief Medical Director for Research and Development in Integrated Oncology and Genomics at ARUP.

    Board Certification and Academic Information

    Academic Departments Pathology -Primary

    Education history

    Fellowship Immunology - Stanford University School of Medicine Postdoctoral Fellow
    Hematopathology - Stanford University School of Medicine Fellow
    Residency Anatomic Pathology - Stanford University School of Medicine Resident
    Health Sciences and Technology Program - Harvard Medical School-Massachusetts Institute of Technology
    Graduate Training Cell and Developmental Biology - Harvard University Ph.D.
    Medicine - Harvard Medical School M.D.
    Undergraduate Molecular Biology - Princeton University A.B.

    Selected Publications

    Journal Article

    1. Guney E, Lucas CG, Qi Z, Yu J, Zhang R, Ohgami RS, Rubenstein JL, Bou DR, Schafernak KT, Wertheim GB, Dahiya S, Giulino-Roth L, Attarbaschi A, Barth MJ, Kothari S, Abla O, Cohen AL, Mendez JS, Bollen AW, Perry A, Tihan T, Pekmezci M, Solomon DA, Wen KW (2022). A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. Blood Adv, 6, 3189-3193.
    2. Butzmann A, Sridhar K, Jangam D, Song H, Singh A, Kumar J, Chisholm KM, Pinsky B, Huang F, Ohgami RS (2022). Mutations in JAK/STAT and NOTCH1 Genes Are Enriched in Post-Transplant Lymphoproliferative Disorders. Front Oncol, 11, 790481.
    3. Ling H, Sridhar K, Gollapudi S, Kumar J, Ohgami RS (2020). Measurement of cell volume using in-line digital holography. Microscopy (Oxf), 70(4), 333-339.
    4. Han SY, Mrzek K, Voutsinas J, Wu Q, Morgan EA, Vestergaard H, Ohgami R, Kluin PM, Kristensen TK, Pullarkat S, Mller MB, Schiefer AI, Baughn LB, Kim Y, Czuchlewski D, Hilberink JR, Horny HP, George TI, Dolan M, Ku NK, Arana Yi C, Pullarkat V, Kohlschmidt J, Salhotra A, Soma L, Bloomfield CD, Chen D, Sperr WR, Marcucci G, Cho C, Akin C, Gotlib J, Broesby-Olsen S, Larson M, Linden MA, Deeg HJ, Hoermann G, Perales MA, Hornick JL, Litzow MR, Nakamura R, Weisdorf D, Borthakur G, Huls G, Valent P, Ustun C, Yeung CCS (2020). Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). Blood Adv, 5(10), 2481-2489.
    5. Yang F, Nielsen SCA, Hoh RA, Rltgen K, Wirz OF, Haraguchi E, Jean GH, Lee JY, Pham TD, Jackson KJL, Roskin KM, Liu Y, Nguyen K, Ohgami RS, Osborne EM, Nadeau KC, Niemann CU, Parsonnet J, Boyd SD (2021). Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues. Science, 372(6543), 738-741.
    6. Singh K, Mittal S, Gollapudi S, Butzmann A, Kumar J, Ohgami RS (2020). A meta-analysis of SARS-CoV-2 patients identifies the combinatorial significance of D-dimer, C-reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity. Int J Lab Hematol, 43(2), 324-328.
    7. Gollapudi S, Singh K, Small C, Mukherjee S, Ohgami RS (2021). Evaluation and creation of efficient pathology research pipelines for discovery: cost-effective tissue microarray construction coupled with automated digital image analysis. J Clin Transl Pathol, 1(1), 28-31.
    8. Jangam D, Sridhar K, Butzmann A, Samghabadi P, Plowey ED, Ohgami RS (2020). TBL1XR1 Mutations in Primary Marginal Zone Lymphomas of Ocular Adnexa are Associated with Unique Morphometric Phenotypes. Curr Eye Res, 45(12), 1583-1589.
    9. Brar N, Butzmann A, Kumar J, Peerani R, Morgan EA, Grigoriadis G, Kumar B, Tatarczuch RM, Warnke RA, Ohgami RS (2020). LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations. Histopathology, 77(6), 984-988.
    10. Butzmann A, Sridhar K, Jangam D, Kumar J, Sahoo MK, Shahmarvand N, Warnke R, Rangasamy E, Pinsky BA, Ohgami RS (2020). A comprehensive analysis of RHOA mutation positive and negative angioimmunoblastic T-cell lymphomas by targeted deep sequencing, expression profiling and single cell digital image analysis. Int J Mol Med, 46(4), 1466-1476.
    11. Hoffmann JC, Atwater SK, Hong E, Kumar J, Khodadoust M, Kim Y, Ohgami RS (2020). A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival. Am J Dermatopathol, 42(6), 389-396.
    12. Werstein B, Dunlap J, Cascio MJ, Ohgami RS, Fan G, Press R, Raess PW (2019). Molecular Discordance between Myeloid Sarcomas and Concurrent Bone Marrows Occurs in Actionable Genes and Is Associated with Worse Overall Survival. J Mol Diagn, 22(3), 338-345.
    13. Tsai AG, Glass DR, Juntilla M, Hartmann FJ, Oak JS, Fernandez-Pol S, Ohgami RS, Bendall SC (2020). Multiplexed single-cell morphometry for hematopathology diagnostics. Nat Med, 26(3), 408-417.
    14. Jangam D, Butzmann A, Sridhar K, Deresinski S, Banaei N, Ohgami RS (2020). The significance of bacterial and viral genotypes as a risk factor in driving cancer. Mol Clin Oncol.
    15. Hoffmann JC, Lin CY, Bhattacharyya S, Weinberg OK, Chisholm KM, Bayerl M, Cascio M, Venkataraman G, Allison K, Troxell M, Chang CC, Bagg A, George TI, OMalley D, Ohgami RS (2019). Rosai-Dorfman Disease of the Breast With Variable IgG4+ Plasma Cells: A Diagnostic Mimicker of Other Malignant and Reactive Entities. Am J Surg Pathol, 43(12), 1653-1660.
    16. Singh A, Ohgami RS (2018). Super-Resolution Digital Pathology Image Processing of Bone Marrow Aspirate and Cytology Smears and Tissue Sections. J Pathol Inform, 9, 48.
    17. Lau H, Nagy A, Atwater SK, Cascio MJ, Ohgami RS (2018). An integrated flow cytometry analysis of 286 mature B cell neoplasms identifies CD13 as a useful marker for diagnostic subtyping. Int J Lab Hematol, 40(6), 715-720.
    18. Mi X, Griffin G, Lee W, Patel S, Ohgami R, Ok CY, Wang S, Geyer JT, Xiao W, Roshal M, Garcia JS, Silverman LB, Sallan SE, Aster JC, Harris MH, Weinberg OK (2018). Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. Am J Hematol, 93(11), 1358-1367.
    19. Gars E, Purington N, Scott G, Chisholm K, Gratzinger D, Martin BA, Ohgami RS (2018). Bone marrow histomorphological criteria can accurately diagnose hemophagocytic lymphohistiocytosis. Haematologica, 103(10), 1635-1641.
    20. Ustun C, Morgan E, Moodie EEM, Pullarkat S, Yeung C, Broesby-Olsen S, Ohgami R, Kim Y, Sperr W, Vestergaard H, Chen D, Kluin PM, Dolan M, Mrzek K, Czuchlewski D, Horny HP, George TI, Kristensen TK, Ku NK, Yi CA, Mller MB, Marcucci G, Baughn L, Schiefer AI, Hilberink JR, Pullarkat V, Shanley R, Kohlschmidt J, Coulombe J, Salhotra A, Soma L, Cho C, Linden MA, Akin C, Gotlib J, Hoermann G, Hornick J, Nakamura R, Deeg J, Bloomfield CD, Weisdorf D, Litzow MR, Valent P, Huls G, Perales MA, Borthakur G (2018). Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). Cancer Med, 7(9), 4447-4455.
    21. Nagy A, Bhaduri A, Shahmarvand N, Shahryari J, Zehnder JL, Warnke RA, Mughal T, Ali S, Ohgami RS (2017). Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. Blood Adv, 2(5), 481-491.
    22. Shahmarvand N, Oak JS, Cascio MJ, Alcasid M, Goodman E, Medeiros BC, Arber DA, Zehnder JL, Ohgami RS (2017). A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia. Int J Lab Hematol, 39(4), 375-383.
    23. Kunder C, Cascio MJ, Bakke A, Venkataraman G, OMalley DP, Ohgami RS (2017). Predominance of CD4+ T Cells in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma and Identification of a Subset of Patients With Peripheral B-Cell Lymphopenia. Am J Clin Pathol, 147(6), 596-603.
    24. Koo M, Ohgami RS (2017). Pediatric-type Follicular Lymphoma and Pediatric Nodal Marginal Zone Lymphoma: Recent Clinical, Morphologic, Immunophenotypic, and Genetic Insights. Adv Anat Pathol, 24(3), 128-135.
    25. Alcasid M, Ma L, Gotlib JR, Arber DA, Ohgami RS (2017). The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia. Int J Lab Hematol, 39(2), 129-136.
    26. Chisholm KM, Ohgami RS, Tan B, Hasserjian RP, Weinberg OK (2016). Primary lymphoma of bone in the pediatric and young adult population. Hum Pathol, 60, 1-10.
    27. Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, Lovejoy AF, Chabon JJ, Klass DM, Liu CL, Zhou L, Glover C, Visser BC, Poultsides GA, Advani RH, Maeda LS, Gupta NK, Levy R, Ohgami RS, Kunder CA, Diehn M, Alizadeh AA (2016). Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med, 8(364), 364ra155.
    28. Duncavage E, Advani RH, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, OMalley DP, Patel KP, Rosenbaum JN, Wilson C, Members of the Cancer Biomarker Reporting Committee College of American Pathologists (2016). Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Arch Pathol Lab Med, 140(11), 1225-1227.
    29. Duncavage E, Advani RH, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, OMalley DP, Patel KP, Rosenbaum JN, Wilson C, Members of the Cancer Biomarker Reporting Committee College of American Pathologists (2016). Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Arch Pathol Lab Med, 140(11), 1228-1230.
    30. Ozawa MG, Bhaduri A, Chisholm KM, Baker SA, Ma L, Zehnder JL, Luna-Fineman S, Link MP, Merker JD, Arber DA, Ohgami RS (2016). A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Mod Pathol, 29(10), 1212-20.
    31. Fernandez-Pol S, Ma L, Ohgami RS, Arber DA (2016). Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Mod Pathol, 29(9), 996-1003.
    32. Hoffmann JC, Chisholm KM, Cherry A, Chen J, Arber DA, Natkunam Y, Warnke RA, Ohgami RS (2015). An analysis of MYC and EBV in diffuse large B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified. Hum Pathol, 48, 9-17.
    33. Weinberg OK, Rodig SJ, Pozdnyakova O, Ren L, Arber DA, Ohgami RS (2015). Surface Light Chain Expression in Primary Mediastinal Large B-Cell Lymphomas by Multiparameter Flow Cytometry. Am J Clin Pathol, 144(4), 635-41.
    34. Johnson RC, Weinberg OK, Cascio MJ, Dahl GV, Mitton BA, Silverman LB, Cherry AM, Arber DA, Ohgami RS (2015). Cytogenetic Variation of B-Lymphoblastic Leukemia With Intrachromosomal Amplification of Chromosome 21 (iAMP21): A Multi-Institutional Series Review. Am J Clin Pathol, 144(1), 103-12.
    35. Kurtz DM, Green MR, Bratman SV, Scherer F, Liu CL, Kunder CA, Takahashi K, Glover C, Keane C, Kihira S, Visser B, Callahan J, Kong KA, Faham M, Corbelli KS, Miklos D, Advani RH, Levy R, Hicks RJ, Hertzberg M, Ohgami RS, Gandhi MK, Diehn M, Alizadeh AA (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125(24), 3679-87.
    36. Ohgami RS, Ma L, Merker JD, Gotlib JR, Schrijver I, Zehnder JL, Arber DA (2014). Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol, 28(5), 706-14.
    37. Chisholm KM, Merker JD, Gotlib JR, Gitana G, Lefterova M, Zehnder JL, George TI, Arber DA, Ohgami RS (2015). Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Am J Clin Pathol, 143(4), 527-34.
    38. Ohgami RS, Zhao S, Natkunam Y (2014). Large B-cell lymphomas poor in B cells and rich in PD-1+ T cells can mimic T-cell lymphomas. Am J Clin Pathol, 142(2), 150-6.
    39. Weinberg OK, Ohgami RS, Ma L, Seo K, Ren L, Gotlib JR, Seetharam M, Cherry A, Arber DA (2014). Acute myeloid leukemia with monosomal karyotype: morphologic, immunophenotypic, and molecular findings. Am J Clin Pathol, 142(2), 190-5.
    40. Ohgami RS, Chisholm KM, Ma L, Arber DA (2014). E-cadherin is a specific marker for erythroid differentiation and has utility, in combination with CD117 and CD34, for enumerating myeloblasts in hematopoietic neoplasms. Am J Clin Pathol, 141(5), 656-64.
    41. Ohgami RS, Ma L, Ren L, Weinberg OK, Seetharam M, Gotlib JR, Arber DA (2012). DNA methylation analysis of ALOX12 and GSTM1 in acute myeloid leukaemia identifies prognostically significant groups. Br J Haematol, 159(2), 182-90.
    42. Ohgami RS, Ohgami JK, Pereira IT, Gitana G, Zehnder JL, Arber DA (2011). Refining the diagnosis of T-cell large granular lymphocytic leukemia by combining distinct patterns of antigen expression with T-cell clonality studies. Leukemia, 25(9), 1439-43.
    43. Younes SF, Beck AH, Ohgami RS, Lossos IS, Levy R, Warnke RA, Natkunam Y (2011). The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow. Am J Clin Pathol, 135(5), 697-708.
    44. Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK (2010). PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol, 24(3), 412-24.
    45. Sendamarai AK, Ohgami RS, Fleming MD, Lawrence CM (2008). Structure of the membrane proximal oxidoreductase domain of human Steap3, the dominant ferrireductase of the erythroid transferrin cycle. Proc Natl Acad Sci U S A, 105(21), 7410-5.
    46. Ohgami RS, Campagna DR, McDonald A, Fleming MD (2006). The Steap proteins are metalloreductases. Blood, 108(4), 1388-94.
    47. Ohgami RS, Campagna DR, Antiochos B, Wood EB, Sharp JJ, Barker JE, Fleming MD (2005). nm1054: a spontaneous, recessive, hypochromic, microcytic anemia mutation in the mouse. Blood, 106(10), 3625-31.
    48. Ohgami RS, Campagna DR, Greer EL, Antiochos B, McDonald A, Chen J, Sharp JJ, Fujiwara Y, Barker JE, Fleming MD (2005). Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet, 37(11), 1264-9.

    Review

    1. Kikuchi A, Singh K, Gars E, Ohgami RS (2022). Pathology updates and diagnostic approaches to haemophagocytic lymphohistiocytosis. [Review]. Histopathology, 80(4), 616-626.
    2. Singh K, Gollapudi S, Mittal S, Small C, Kumar J, Ohgami RS (2021). Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2. [Review]. Diagnostics (Basel), 11(4).
    3. Butzmann A, Kumar J, Sridhar K, Gollapudi S, Ohgami RS (2021). A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease. [Review]. Biology (Basel), 10(4).
    4. Lauw MIS, Lucas CG, Ohgami RS, Wen KW (2020). Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features. [Review]. Diagnostics (Basel), 10(12).
    5. Yao K, Singh A, Sridhar K, Blau JL, Ohgami RS (2020). Artificial Intelligence in Pathology: A Simple and Practical Guide. [Review]. Adv Anat Pathol, 27(6), 385-393.
    6. Wen KW, Fakhri B, Menke J, Ruiz-Cordero R, Gill RM, Ohgami RS (2020). Complexities in the diagnosis of large B-cell lymphomas, classic Hodgkin lymphomas and overlapping peripheral T-cell lymphomas simplified: An evidence-based guide. [Review]. Ann Diagn Pathol, 46, 151534.
    7. Gars E, Butzmann A, Ohgami R, Balakrishna JP, OMalley DP (2019). The life and death of the germinal center. [Review]. Ann Diagn Pathol, 44, 151421.
    8. Sridhar K, Singh A, Butzmann A, Jangam D, Ohgami RS (2018). Molecular genetic testing methodologies in hematopoietic diseases: current and future methods. [Review]. Int J Lab Hematol, 41 Suppl 1, 102-116.
    9. Shahmarvand N, Nagy A, Shahryari J, Ohgami RS (2018). Mutations in the signal transducer and activator of transcription family of genes in cancer. [Review]. Cancer Sci, 109(4), 926-933.
    10. Ohgami RS, Arber DA (2015). The diagnostic and clinical impact of genetics and epigenetics in acute myeloid leukemia. [Review]. Int J Lab Hematol, 37 Suppl 1, 122-32.
    11. Ohgami RS, Arber DA, Zehnder JL, Natkunam Y, Warnke RA (2013). Indolent T-lymphoblastic proliferation (iT-LBP): a review of clinical and pathologic features and distinction from malignant T-lymphoblastic lymphoma. [Review]. Adv Anat Pathol, 20(3), 137-40.

    Book Chapter

    1. Ohgami RS, Arber DA (2016). Chapter 22. Disorders of the Spleen. In Hsi E (Ed.), Hematopathology (3rd edition). Elsevier.
    2. Ohgami RS, Arber DA (2015). Bone marrow therapy changes. In Hsi E (Ed.), Hematopathology (2nd edition). Elsevier.
    3. Ohgami RS, Arber DA (2013). Challenges in consolidated reporting of hematopoietic neoplasms. In George T, Arber DA (Eds.), Hematopoietic Neoplasms: Controversies in Diagnosis and Classification, An Issue of Surgical Pathology Clinics. Elsevier.
    4. Ohgami RS, Ziai JM, Arber DA (2012). Chapter 22. Disorders of the Spleen. In Hsi E (Ed.), Hematopathology (2nd edition). Elsevier.

    Commentary

    1. Ohgami RS, Rosenwald A, Bagg A (2018). Next-Generation Sequencing for Lymphomas: Perfecting a Pipeline for Personalized Pathobiologic and Prognostic Predictions. J Mol Diagn, 20(2), 163-165.

    Case Report

    1. Chen JA, Hou Y, Roskin KM, Arber DA, Bangs CD, Baughn LB, Cherry AM, Ewalt MD, Fire AZ, Fresard L, Kearney HM, Montgomery SB, Ohgami RS, Pearce KE, Pitel BA, Merker JD, Gotlib J (2021). Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. Blood Adv, 5(17), 3492-3496.
    2. Kennedy VE, Ruiz-Cordero R, Jangam D, Wen KW, Dunavin N, Ohgami RS, Bhargava P, Ai W, Fakhri B (2021). A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care. Clin Lymphoma Myeloma Leuk, 21(7), e583-e587.
    3. Wang L, Ashraf DC, Kinde B, Ohgami RS, Kumar J, Kersten RC (2020). Hypodiploid B-Lymphoblastic Leukemia Presenting as an Isolated Orbital Mass Prior to Systemic Involvement: A Case Report and Review of the Literature. Diagnostics (Basel), 11(1).
    4. Kumar J, Butzmann A, Wu S, Easly S, Zehnder JL, Warnke RA, Bangs CD, Jangam D, Cherry A, Lau J, Nybakken G, Ohgami RS (2019). Indolent In Situ B-Cell Neoplasms With MYC Rearrangements Show Somatic Mutations in MYC and TNFRSF14 by Next-generation Sequencing. Am J Surg Pathol, 43(12), 1720-1725.
    5. Li P, Shahmarvand N, Lynch D, Gotlib JR, Merker JD, Zehnder JL, George TI, Ohgami RS (2019). Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist. Int J Lab Hematol, 41(3), 345-352.
    6. Thauland TJ, Pellerin L, Ohgami RS, Bacchetta R, Butte MJ (2019). Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome. Front Immunol, 10, 753.
    7. Farris M, Hughes RT, Lamar Z, Soike MH, Menke JR, Ohgami RS, Winkfield K (2018). Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature. Clin Lymphoma Myeloma Leuk, 19(1), e1-e8.
    8. Sumarriva Lezama L, Chisholm KM, Carneal E, Nagy A, Cascio MJ, Yan J, Chang CC, Cherry A, George TI, Ohgami RS (2018). An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality. Histopathology, 73(5), 767-776.
    9. Lo C, Alvarez E, Ohgami RS, Jeng M (2017). Case Report: Clinical Variation in Children With Thrombopoietin Receptor (C-MPL) Mutations: Report of 2 Cases. J Pediatr Hematol Oncol, 40(1), 67-70.
    10. Chung A, Hou Y, Ohgami RS, Von Gehr A, Fisk DG, Roskin KM, Li X, Gojenola L, Bangs CD, Arber DA, Fire AZ, Cherry AM, Zehnder JL, Gotlib J, Merker JD (2017). A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. Cancer Genet, 216-217, 10-15.
    11. Karnik T, Ozawa MG, Lefterova M, Luna-Fineman S, Alvarez E, Link M, Zehnder JL, Arber DA, Ohgami RS (2015). The utility of IgM, CD21, HGAL and LMO2 in the diagnosis of pediatric follicular lymphoma. Hum Pathol, 46(4), 629-33.
    12. Chalmers ZR, Ali SM, Ohgami RS, Campregher PV, Frampton GM, Yelensky R, Elvin JA, Palma NA, Erlich R, Vergilio JA, Chmielecki J, Ross JS, Stephens PJ, Hermann R, Miller VA, Miles CR (2015). Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy. Blood Cancer J, 5, e278.
    13. Ohgami RS, Sendamarai AK, Atwater SK, Liedtke M, Fleming MD, Natkunam Y, Warnke RA (2014). Indolent T-lymphoblastic proliferation with disseminated multinodal involvement and partial CD33 expression. Am J Surg Pathol, 38(9), 1298-304.
    14. Ewalt MD, Abeynayake J, Waggoner JJ, Pinsky BA, Ohgami RS (2013). Profound plasmacytosis in a patient with dengue. Int J Hematol, 98(5), 518-9.
    15. Ohgami RS, Zhao S, Ohgami JK, Leavitt MO, Zehnder JL, West RB, Arber DA, Natkunam Y, Warnke RA (2012). TdT+ T-lymphoblastic populations are increased in Castleman disease, in Castleman disease in association with follicular dendritic cell tumors, and in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol, 36(11), 1619-28.

    Editorial

    1. Lezama L, Ohgami RS (2019). Expounding on the essence of epigenetic and genetic abnormalities in blastic plasmacytoid dendritic cell neoplasms. Haematologica, 104(4), 642-643.
    2. Oak JS, Ohgami RS (2017). Focusing on frequent ASXL1 mutations in myeloid neoplasms, and considering rarer ASXL2 and ASXL3 mutations. Curr Med Res Opin, 33(4), 781-782.

    Letter

    1. Ustun C, Morgan EA, Ritz EM, Vestergaard H, Pullarkat S, Kluin PM, Ohgami R, Baughn LB, Kim Y, Ku NK, Czuchlewski D, Boe Mller M, Schiefer AI, Mrzek K, Horny HP, George TI, Kielsgaard Kristensen T, Beck T, Nathan S, Arana Yi C, Yeung C, Pullarkat V, Gotlib J, Akin C, Kohlschmidt J, Salhotra A, Soma L, Chen D, Han SY, Cho C, Sperr W, Broesby-Olsen S, Linden MA, Dolan M, Hoermann G, Hornick JL, Bloomfield C, Nakamura R, Joachim Deeg H, Litzow MR, Borthakur G, Weisdorf D, Huls G, Perales MA, Valent P, Marcucci G (2020). Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. [Letter to the editor]. Int J Lab Hematol, 43(1), e19-e25.
    2. Barry-Holson K, Steiner D, Wendroth S, Cherry A, Zehnder JL, Ohgami RS (2017). A cytogenetically cryptic case of an otherwise obvious acute promyelocytic leukemia: the importance of real time PCR molecular analysis [Letter to the editor]. Human Pathology: Case Reports, 10, 102-3.
    3. Ohgami RS, Natkunam Y, Warnke RA (2015). Indolent T-lymphoblastic proliferation: a name with specific meaning. [Letter to the editor]. Hum Pathol, 46(11), 1785-6.
    4. Ohgami RS, Ma L, Monabati A, Zehnder JL, Arber DA (2014). STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. [Letter to the editor]. Haematologica, 99(7), e105-7.
    5. Ohgami RS, Ma L, Merker JD, Martinez B, Zehnder JL, Arber DA (2013). STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. [Letter to the editor]. Leukemia, 27(11), 2244-7.
    6. Kohrt HE, Ohgami RS, Arber DA, Alizadeh A, Coutre S (2011). Diagnosing PNH in the era of FLAER [Letter to the editor]. Blood.

    Video/Film/CD/Web/Podcast

    1. Chalmers AR, Frampton GM, Ali SM, Ohgami RS, Miles CR (2016). T(4;10)(q12;q23) PDGFRA/TNKS2 [Web]. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available: http://AtlasGeneticsOncology.org/Anomalies/t0410qq12q23ID1468.html.
    2. Ozawa M, Ohgami RS (2016). Pediatric type follicular lymphoma [Web]. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available: http://AtlasGeneticsOncology.org/Anomalies/PediatrFLID1749.html.
    3. Shahmarvand N, Ohgami RS (2016). MDS with isolated del(5q) [Web]. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available: http://AtlasGeneticsOncology.org/Anomalies/del5qSoleID1134.html.
    4. Sharyari J, Ohgami RS (2016). Follicular dendritic cell sarcomas [Web]. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available: http://AtlasGeneticsOncology.org/Anomalies/FollDendriticCellSarcID1719.html.
    5. Koo M, Ohgami RS (2016). MDS/MPN with ring sideroblasts and thrombocytosis [Web]. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Available: http://AtlasGeneticsOncology.org/Anomalies/MDS-MPN-RS-TID1396.html.